Shares of Endologix, Inc. (NASDAQ:ELGX) have earned a consensus recommendation of “Hold” from the twelve ratings firms that are currently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $5.36.
Several equities analysts have weighed in on ELGX shares. ValuEngine lowered Endologix from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. JPMorgan Chase & Co. lowered Endologix from a “neutral” rating to an “underweight” rating in a report on Tuesday, January 2nd. Royal Bank of Canada cut their price target on Endologix from $5.00 to $4.00 and set a “sector perform” rating for the company in a report on Wednesday, November 8th. Piper Jaffray Companies reaffirmed an “overweight” rating on shares of Endologix in a report on Tuesday, December 12th. Finally, BidaskClub lowered Endologix from a “hold” rating to a “sell” rating in a report on Friday, January 19th.
A number of large investors have recently bought and sold shares of the stock. Schwab Charles Investment Management Inc. raised its position in Endologix by 10.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 321,309 shares of the medical instruments supplier’s stock valued at $1,562,000 after purchasing an additional 30,429 shares in the last quarter. Swiss National Bank increased its holdings in shares of Endologix by 14.3% in the second quarter. Swiss National Bank now owns 137,900 shares of the medical instruments supplier’s stock worth $670,000 after buying an additional 17,300 shares during the period. Alliancebernstein L.P. increased its holdings in Endologix by 11.5% during the 2nd quarter. Alliancebernstein L.P. now owns 108,757 shares of the medical instruments supplier’s stock valued at $529,000 after purchasing an additional 11,200 shares during the period. Teachers Advisors LLC increased its holdings in Endologix by 40.8% during the 2nd quarter. Teachers Advisors LLC now owns 198,912 shares of the medical instruments supplier’s stock valued at $967,000 after purchasing an additional 57,675 shares during the period. Finally, TIAA CREF Investment Management LLC boosted its position in Endologix by 48.5% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 324,193 shares of the medical instruments supplier’s stock valued at $1,576,000 after acquiring an additional 105,895 shares in the last quarter.
Shares of Endologix (ELGX) traded up $0.11 on Tuesday, hitting $4.32. The company had a trading volume of 712,538 shares, compared to its average volume of 790,588. The company has a quick ratio of 2.11, a current ratio of 2.90 and a debt-to-equity ratio of 2.61. The stock has a market capitalization of $360.52, a P/E ratio of -4.65 and a beta of 0.42. Endologix has a one year low of $3.77 and a one year high of $7.66.
WARNING: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/18/endologix-inc-elgx-receives-5-36-consensus-price-target-from-brokerages.html.
Endologix Company Profile
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.